Literature DB >> 32593453

Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC.

Viola W Zhu1, Russell Madison2, Alexa B Schrock2, Sai-Hong Ignatius Ou3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32593453     DOI： 10.1016/j.jtho.2020.03.020

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

Review 1.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

2.  The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.

Authors:  Ezra Y Rosen; Helen H Won; Barry S Taylor; Alexander Drilon; Youyun Zheng; Emiliano Cocco; Duygu Selcuklu; Yixiao Gong; Noah D Friedman; Ino de Bruijn; Onur Sumer; Craig M Bielski; Casey Savin; Caitlin Bourque; Christina Falcon; Nikeysha Clarke; Xiaohong Jing; Fanli Meng; Catherine Zimel; Sophie Shifman; Srushti Kittane; Fan Wu; Marc Ladanyi; Kevin Ebata; Jennifer Kherani; Barbara J Brandhuber; James Fagin; Eric J Sherman; Natasha Rekhtman; Michael F Berger; Maurizio Scaltriti; David M Hyman
Journal:  Nat Commun       Date:  2022-03-18       Impact factor: 14.919

3.  Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer.

Authors:  Renuka Raman; Jacques A Villefranc; Timothy M Ullmann; Jessica Thiesmeyer; Viviana Anelli; Jun Yao; James R Hurley; Chantal Pauli; Rohan Bareja; Kenneth Wha Eng; Princesca Dorsaint; David C Wilkes; Shaham Beg; Sarah Kudman; Reid Shaw; Michael Churchill; Adnan Ahmed; Laurel Keefer; Ian Misner; Donna Nichol; Naveen Gumpeni; Theresa Scognamiglio; Mark A Rubin; Carla Grandori; James Patrick Solomon; Wei Song; Juan Miguel Mosquera; Noah Dephoure; Andrea Sboner; Olivier Elemento; Yariv Houvras
Journal:  J Exp Med       Date:  2022-05-05       Impact factor: 17.579

Review 4.  RET signaling pathway and RET inhibitors in human cancer.

Authors:  Angelina T Regua; Mariana Najjar; Hui-Wen Lo
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

5.  Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.

Authors:  J J Lin; S V Liu; C E McCoach; V W Zhu; A C Tan; S Yoda; J Peterson; A Do; K Prutisto-Chang; I Dagogo-Jack; L V Sequist; L J Wirth; J K Lennerz; A N Hata; M Mino-Kenudson; V Nardi; S-H I Ou; D S-W Tan; J F Gainor
Journal:  Ann Oncol       Date:  2020-09-29       Impact factor: 51.769

Review 6.  Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.

Authors:  Sara Fancelli; Enrico Caliman; Francesca Mazzoni; Marco Brugia; Francesca Castiglione; Luca Voltolini; Serena Pillozzi; Lorenzo Antonuzzo
Journal:  Cancers (Basel)       Date:  2021-03-04       Impact factor: 6.639

Review 7.  New approaches for patients with advanced radioiodine-refractory thyroid cancer.

Authors:  Fabián Pitoia; Fernando Jerkovich; Pierpaolo Trimboli; Anabella Smulever
Journal:  World J Clin Oncol       Date:  2022-01-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.